Botulinum neurotoxin: Not only in Dermatology - Expanding Therapeutic Horizons Across Medical Specialties
DOI:
https://doi.org/10.12775/JEHS.2026.87.68236Keywords
botulinum neurotoxin, botulinum toxic type A, BTX-A., Dermatology, neurology, Urology, Gastroenterology, wound healing, Hyperhidrosis, focal dystonia, spasticity, migraine, neuropathic pain, overactive bladder, urinary incontinence, interstitial cystitis, Hirschsprung’s disease, gastroparesis, chronic anal fissure, depression, immunomodulationAbstract
Background. Botulinum neurotoxin (BTX) is commonly associated with cosmetic applications; however, its therapeutic relevance extends far beyond aesthetic medicine. Through inhibition of presynaptic acetylcholine release, BTX induces reversible chemodenervation and modulates sensory, autonomic, and inflammatory signaling, providing a biological basis for its wide range of clinical applications across multiple medical specialties.
Aim. The aim of this review was to summarize and critically appraise current evidence on established and emerging therapeutic applications of botulinum neurotoxin in dermatology, neurology, urology, gastroenterology, and selected novel indications.
Material and methods. A narrative review of the literature was conducted using recent clinical studies, systematic reviews, meta-analyses, and relevant experimental research focusing on the mechanisms of action, clinical efficacy, and safety of botulinum neurotoxin across different medical disciplines.
Results. Botulinum neurotoxin demonstrates well-established efficacy and an acceptable safety profile in dermatology, particularly in wound healing and hyperhidrosis, and in neurology, where it represents a cornerstone therapy for focal dystonias, spasticity, chronic migraine, and selected pain syndromes. In urology and gastroenterology, BTX provides effective, minimally invasive treatment options for refractory lower urinary tract dysfunctions and selected gastrointestinal and anorectal disorders. Emerging evidence further suggests potential roles for BTX in depression and immunomodulation.
Conclusions. Botulinum neurotoxin has evolved into a versatile therapeutic agent with broad clinical applicability across multiple medical specialties. While its established indications are supported by robust evidence, emerging applications highlight promising new therapeutic directions that warrant further high-quality clinical and translational research.
References
1. Dressler D, Johnson EA. Botulinum toxin therapy: past, present and future developments. J Neural Transm (Vienna). Jun 2022;129(5-6):829-833. doi:10.1007/s00702-022-02494-5
2. Santamato A. Botulinum Neurotoxins: From Toxin to Medicine. Toxins (Basel). Oct 20 2023;15(10)doi:10.3390/toxins15100621
3. Scott AB, Honeychurch D, Brin MF. Early development history of Botox (onabotulinumtoxinA). Medicine (Baltimore). Jul 1 2023;102(S1):e32371. doi:10.1097/MD.0000000000032371
4. Zhou Y, He Z, Xiang T, et al. Safety and efficacy of intravesical instillation of botulinum toxin-A in the treatment of interstitial cystitis/bladder pain syndrome and overactive bladder: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1586845. doi:10.3389/fphar.2025.1586845
5. Lin J, Wang X. RETRACTED: Effects of botulinum toxin type A in the prevention and treatment of facial hypertrophic scars: A meta-analysis. International Wound Journal. 2024;21(3):e14796. doi:https://doi.org/10.1111/iwj.14796
6. Kasyanju Carrero LM, Ma WW, Liu HF, Yin XF, Zhou BR. Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: Updated review. J Cosmet Dermatol. Feb 2019;18(1):10-15. doi:10.1111/jocd.12828
7. Jiang A, Jiang R, Liu T. A Meta-Analysis of the Efficacy and Safety of Botulinum Toxin Type A for the Management of Scars After Facial Surgery. Journal of Cosmetic Dermatology. 2025;24(3):e70111. doi:https://doi.org/10.1111/jocd.70111
8. Gökşin Ş, İmren IG. Internalized stigma, disease severity, quality of life, anxiety and depression in axillary hyperhidrosis. Ann Dermatol Venereol. Sep 2024;151(3):103291. doi:10.1016/j.annder.2024.103291
9. Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review. Toxins (Basel). Feb 5 2021;13(2)doi:10.3390/toxins13020120
10. Moniati F, Vassiliou M, Costa C, Chatzimatthaiou C, Chatzimatthaiou M. Efficacy and Safety of Treatments for Primary Palmar Hyperhidrosis: A Systematic Review Assessing Patient-Centric Outcomes. Dermatology Research and Practice. 2025;2025(1):8867838. doi:https://doi.org/10.1155/drp/8867838
11. Campanati A, Martina E, Gregoriou S, et al. Botulinum Toxin Type A for Treatment of Forehead Hyperhidrosis: Multicenter Clinical Experience and Review from Literature. Toxins (Basel). May 27 2022;14(6)doi:10.3390/toxins14060372
12. Alsaati AA, Alsaadoun D, Kinkar LI, Alkhamis RS, Ahmed WA, Almathami AH. The Efficacy and Safety of Botulinum Toxin A for the Treatment of Rosacea: A Systematic Review. Cureus. Dec 2023;15(12):e51304. doi:10.7759/cureus.51304
13. Gazerani P. How Does Botulinum Toxin Inhibit Itch? Toxins (Basel). Oct 12 2022;14(10)doi:10.3390/toxins14100701
14. Anandan C, Jankovic J. Botulinum Toxin in Movement Disorders: An Update. Toxins (Basel). Jan 8 2021;13(1)doi:10.3390/toxins13010042
15. Slawek J, Jost WH. Botulinum neurotoxin in neurological practice - a leading topic in neurology. Neurol Neurochir Pol. 2021;55(2):120-124. doi:10.5603/PJNNS.a2021.0034
16. Slawek J, Lobinska IA, Schinwelski M, Kopcewicz-Wisniewska J, Castagna A. Case Series and Literature Review on Botulinum Toxin Efficacy in Axial Extensor Truncal Dystonia. Toxins (Basel). Jul 29 2025;17(8)doi:10.3390/toxins17080375
17. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. Jan 2009;41(1):13-25. doi:10.2340/16501977-0303
18. Facciorusso S, Spina S, Picelli A, et al. The Role of Botulinum Toxin Type-A in Spasticity: Research Trends from a Bibliometric Analysis. Toxins (Basel). Apr 9 2024;16(4)doi:10.3390/toxins16040184
19. Paracka L, Dressler D. Botulinum toxin for chronic migraine. J Neural Transm (Vienna). Nov 6 2025;doi:10.1007/s00702-025-03055-2
20. Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. Jun 25 2018;6(6):CD011616. doi:10.1002/14651858.CD011616.pub2
21. Matak I, Bolcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins (Basel). Aug 5 2019;11(8)doi:10.3390/toxins11080459
22. Fabillar Jr J, Yamamoto Y, Koike K, Ikutame D, Matsuka Y. Updates on the Proposed Botulinum Toxin A Mechanisms of Action in Orofacial Pain: A Review of Animal Studies. Toxins. 2025;17(12)doi:10.3390/toxins17120567
23. Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU International. 2013;111(1):106-113. doi:https://doi.org/10.1111/j.1464-410X.2012.11282.x
24. Urology EAo. EAU Guidelines. EAU Annual Congress, Madrid 2025 ed. EAU Guidelines Office; 2025.
25. Hougaard NB, Breinbjerg A, Kamperis K, Skott M. Botulinum Neurotoxin Type A in paediatric non-neurogenic therapy resistant overactive bladder: a cohort study. Int Urol Nephrol. Feb 2025;57(2):341-346. doi:10.1007/s11255-024-04217-z
26. Kuo HC. Lower urinary tract dysfunction in the central nervous system neurogenic bladder and the real-life treatment outcome of botulinum toxin A. Tzu Chi Med J. Jul-Sep 2024;36(3):260-270. doi:10.4103/tcmj.tcmj_29_24
27. Ghanbari Z, Eftekhar T, Deldar M, et al. Evaluation of Clinical Outcomes of Treatment with Botulinum Toxin A Compared to Drug Therapy in Patients with Urge Incontinence: A Clinical Trial Study. The Journal of Obstetrics and Gynecology of India. 2025;doi:10.1007/s13224-025-02242-1
28. Ansari A, Salman M, Najar FA. Benign Prostatic Hyperplasia (BPH) and its Management: A Review of Conventional and Unani Therapeutic Approaches. Journal of Drug Delivery and Therapeutics. 2025;15(7):281-286. doi:10.22270/jddt.v15i7.7285
29. Patel D, Wilder A, Bagwe A, Rodriguez L. Clinical Utility of Botulinum Toxin Injections in Children with Gastrointestinal Disorders. Curr Gastroenterol Rep. Nov 14 2025;27(1):73. doi:10.1007/s11894-025-01023-0
30. Arbizu RA, Rodriguez L. Use of Clostridium botulinum toxin in gastrointestinal motility disorders in children. World J Gastrointest Endosc. May 16 2015;7(5):433-7. doi:10.4253/wjge.v7.i5.433
31. Han-Geurts IJ, Hendrix VC, de Blaauw I, Wijnen MH, van Heurn EL. Outcome after anal intrasphincteric Botox injection in children with surgically treated Hirschsprung disease. J Pediatr Gastroenterol Nutr. Nov 2014;59(5):604-7. doi:10.1097/MPG.0000000000000483
32. Ascanelli S, Rossin E, Aisoni F, et al. Botulinum toxin injection for chronic anal fissure: a prospective controlled study with long follow-up. Minerva Surg. Jun 2024;79(3):293-302. doi:10.23736/S2724-5691.24.10228-6
33. Thippeswamy KM, Gruber M, Abdelaziz H, Abdel-Dayem M. Efficacy and safety of botulinum toxin injection in the management of chronic symptomatic anal fissure: a systematic review and meta-analysis of randomized controlled trials. Tech Coloproctol. Jan 9 2025;29(1):44. doi:10.1007/s10151-024-03087-y
34. Vanaria RJ, Chaudry A, Marrero-Perez AC, Lorenc ZP, Nestor MS. The Face of Emotion: Botulinum Toxin, Emotional Anatomy, and Mood Modulation. J Cosmet Dermatol. Jun 2025;24(6):e70264. doi:10.1111/jocd.70264
35. Gambini M, Gurrieri R, Russomanno G, et al. Botulinum Toxin: An Unconventional Tool for the Treatment of Depression? Brain Sci. Sep 10 2025;15(9)doi:10.3390/brainsci15090971
36. Novo Pereira I, Durao S, Hassan H, et al. Botulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research. J Neural Transm (Vienna). Dec 2025;132(12):1851-1874. doi:10.1007/s00702-024-02869-w
37. Rodriguez-Cerdeira C, Eckhardt W. Depression Treatment: Is There a Role for Botulinum Toxin Type A? Microorganisms. Dec 17 2024;12(12)doi:10.3390/microorganisms12122615
38. Jung D, Shin S, Kim KH, Kim KJ, Park EJ. Botulinum Toxin A Modulates Keratinocyte Proliferation and Inflammatory and Pruritic Mediators in Wound Healing. Ann Dermatol. Oct 2025;37(5):269-275. doi:10.5021/ad.25.063
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Klaudia Kurzątkowska, Dominika Marszałek, Aleksandra Ocimek, Michalina Czudowska, Magdalena Zawadzka, Emilia Borychowska, Karolina Gwóźdź, Zofia Aneta Mierzejewska, Marta Drozdowska, Aleksandra Natalia Bytros
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 3
Number of citations: 0
